Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report

BACKGROUND: Kinase domain duplication of EGFR (EGFR-KDD) is a rare oncogenic driver alteration and serves as a potential therapeutic target. Its effect on EGFR–tyrosine kinase inhibitors (TKIs), especially the third-generation drug Osimertinib, and immune checkpoint inhibitors (ICIs) remains inconcl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jie, Yan, Junrong, Cao, Ran, Du, Guanjun, Zhao, Guofang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773813/
https://www.ncbi.nlm.nih.gov/pubmed/33392076
http://dx.doi.org/10.3389/fonc.2020.575739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773813/
https://www.ncbi.nlm.nih.gov/pubmed/33392076
http://dx.doi.org/10.3389/fonc.2020.575739

Ejemplares similares